ROCHE_WEB THUMBNAIL

April 16, 2024

Faricimab – The Fight Against Retinal Diseases

Faricimab (Vabysmo) is the first approved bispecific antibody uniquely engineered to block two key pathways driving retinal vascular disease by…

popular posts

WhatsApp Image 2025 04 02 at 14.00.38_959c1658

April 3, 2025

Bausch + Lomb’s SeeLuma™ is Launching in India. Here’s What You Need to Know.

[Heidelberg] Website article thumbnail 01

April 9, 2025

Visualizing the Retinal Vasculature

Thumbnail Article_Article 1

April 3, 2025

The Hottest Controversies in Medical Retina, Explained, at APAO 2025

latest posts

Aflibercept 8mg Has Been Available for Over a Year 01

April 29, 2025

Aflibercept 8mg Has Been Available for Over a Year. Here’s What nAMD Experts Are Saying About Early Experiences.

FDA Rejects Regeneron’s Bid to Extend EYLEA HD Dosing Beyond 16 Weeks

April 22, 2025

FDA Rejects Regeneron’s sBLA to Extend EYLEA HD Dosing Interval

Eylea HD for Macular Edema Following RVO

April 18, 2025

FDA Grants Priority Review to Eylea HD for Macular Edema Following RVO

unnamed (22)

April 16, 2025

FDA Grants RMAT Designation to Atsena Therapeutics’ Gene Therapy for X-linked Retinoschisis

Apr11_Article

April 11, 2025

NexThera, Oculis and Bayer Report Advances in Retinal Disease Therapies

Thumbnail Article_Article 4 (1)

April 6, 2025

Eyeing the Future of AMD at APAO 2025

Thumbnail Article_Article 3

April 5, 2025

Key Retinal Debates Sizzle in APAO-AIOC 2025 India AAO Symposium

Article #1

April 5, 2025

Retina Talks, Powered by Women: WIO Symposium at APAO 2025

Discover our fascinating content at issuu

explore